Completion of data collection in Vivosight OCT trial for BCC diagnosis

5 March 2014 – Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces that it has completed scanning and data collection for a large 250-patient, multi-centre, prospective clinical trial of the diagnostic performance of its VivoSight™ OCT scanner in diagnosing superficial basal cell carcinoma (BCC), the most common form of skin cancer.

Click here to download the full press release in pdf format